摘要
目的:评价非甾体类抗炎药吲哚美辛预防经内镜逆行胰胆管造影术(endoscopic retrograde cholangio-pancreatography,ERCP)后胰腺炎(post-endoscopic retrograde cholangiopancreato-graphy pancreatitis,PEP)的有效性.方法:计算机检索PubMed、Embase、中国生物医学文献数据库、清华同方数据库、万方数据库、维普数据库,全面收集吲哚美辛预防ERCP术后胰腺炎的随机对照试验,由两人独立进行数据提取和文献评价.应用Review Manager5.0进行统计分析.结果:共纳入11项随机对照试验(randomized controlled trials,RCTs),共计2718例行ERCP患者.Meta分析结果显示:应用吲哚美辛可降低PEP的发生率(OR=0.39,95%CI:0.30-0.52,P<0.00001)及高淀粉酶血症的发生率(OR=0.50,95%CI:0.37-0.67,P<0.00001).11个纳入研究均未报告药物相关不良反应.结论:吲哚美辛可以有效降低ERCP术后胰腺炎及术后高淀粉酶血症的发生率.
AIM： To assess the effectiveness and safety of indomethacin in preventing post-endoscopic ret- rograde cholangiopancreatography pancreatitis （PEP）. METHODS： Electronic searches were conducted to retrieve randomized controlled trials （RCTs） comparing indomethacin to placebo in the pre- vention of PEP from the PubMed, Embase, CBM, CNKI, WANFANG and VIP databases. Data col- lection and literature evaluation were performed by two reviewers independently. Review Man- ager 5.0 was used for statistical analysis. RESULTS： A total of 11 RCTs involving 2718 patients were included. The meta-analysis showed that indomethacin could reduce the incidence of PEP （OR = 0.39, 95%CI： 0.30-0.52,P 〈 0.00001） and hyperamylasemia （OR = 0.50, 95%Ch 0.37-0.67, P 〈 0.00001）. CONCLUSION： Indomethacin is safe and ef- fective in reducing the incidence of PEP and hyperamylasemia.
出处
《世界华人消化杂志》
CAS
北大核心
2013年第14期1343-1350,共8页
World Chinese Journal of Digestology
